Obesity or OverweightPhase 3SELENE 2NCT07784270

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

A Phase 3 study testing Lenbelintide in people with Obesity or Overweight and Diabetes Mellitus, Type 2, run by AstraZeneca at 230 sites in 16 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Obesity or Overweight, Diabetes Mellitus, Type 2
What is being tested?: Lenbelintide
Type of treatment: Injection or infusion
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 1,500 participants
Where: 230 sitesin 16 countries
Study dates: 20 Aug 2026to 9 Aug 2028
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Males \& females (inclusive of all gender identities) age ≥18 years
BMI ≥27 kg/m2
Diagnosed with T2DM ≥90 days prior to Screening
HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
History of at least one self-reported unsuccessful attempt to lose body weight in lifetime

Who cannot join

Obesity primarily caused by other endocrine disorders
Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
Significant hepatobiliary disease and/or any of the following results at Screening:
ALT ≥ 3.0 X ULN
AST ≥ 3.0 X ULN
TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome)
Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
Use of insulin therapy for T2DM within 3 months prior to screening

Trial locations and contacts

230 sites in 16 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

230 sites in 16 countries

United States56 sites, 55 recruiting

Research Site
Ames, Iowa, 50010
Not yet recruiting
Research Site
Bakersfield, California, 93309
Not yet recruiting
Research Site
Beltsville, Maryland, 20705
Not yet recruiting
Research Site
Chicago, Illinois, 60640
Not yet recruiting
Research Site
DeSoto, Texas, 75115
Not yet recruiting
Research Site
Doral, Florida, 33172
Not yet recruiting
Research Site
Eatontown, New Jersey, 07724
Not yet recruiting
Research Site
El Paso, Texas, 79935
Not yet recruiting
Research Site
Fairhope, Alabama, 36532
Recruiting
Research Site
Farmington Hills, Michigan, 48336
Not yet recruiting
Research Site
Fayette, Mississippi, 39069
Not yet recruiting
Research Site
Fleming Island, Florida, 32003
Not yet recruiting
Research Site
Fort Lauderdale, Florida, 33316
Not yet recruiting
Research Site
Franklin, Tennessee, 37067
Recruiting
Research Site
Gardena, California, 90247
Recruiting
Research Site
Greensboro, North Carolina, 27408
Withdrawn
Research Site
Houston, Texas, 77099
Recruiting
Research Site
Huntsville, Alabama, 35801
Not yet recruiting
Research Site
Jackson, Tennessee, 38305
Not yet recruiting
Research Site
Kansas City, Missouri, 64112
Not yet recruiting
Research Site
Kansas City, Missouri, 64114
Not yet recruiting
Research Site
Knoxville, Tennessee, 37938
Not yet recruiting
Research Site
Lanham, Maryland, 20706
Not yet recruiting
Research Site
Lenexa, Kansas, 66219
Recruiting
Research Site
Lincoln, California, 95648
Recruiting
Research Site
Little Rock, Arkansas, 72205
Not yet recruiting
Research Site
Manassas, Virginia, 20110
Not yet recruiting
Research Site
Melrose Park, Illinois, 60160
Not yet recruiting
Research Site
Mesa, Arizona, 85213
Not yet recruiting
Research Site
Midland, Texas, 79707
Not yet recruiting
Research Site
Mobile, Alabama, 36608
Not yet recruiting
Research Site
Monroe, Louisiana, 71201
Not yet recruiting
Research Site
Monroe, North Carolina, 28112
Not yet recruiting
Research Site
Newton, Kansas, 67114
Not yet recruiting
Research Site
Norfolk, Virginia, 23504
Recruiting
Research Site
North Dartmouth, Massachusetts, 02747
Not yet recruiting
Research Site
Oak Brook, Illinois, 60523
Not yet recruiting
Research Site
Ocoee, Florida, 34761
Recruiting
Research Site
Omaha, Nebraska, 68114
Not yet recruiting
Research Site
Omaha, Nebraska, 68144
Not yet recruiting
Research Site
Oxon Hill, Maryland, 20745
Not yet recruiting
Research Site
Pasadena, Texas, 77504
Not yet recruiting
Research Site
Phoenix, Arizona, 85044
Recruiting
Research Site
Rockville, Maryland, 20852
Not yet recruiting
Research Site
San Antonio, Texas, 78207
Not yet recruiting
Research Site
San Antonio, Texas, 78215
Not yet recruiting
Research Site
San Antonio, Texas, 78258
Not yet recruiting
Research Site
Scottdale, Pennsylvania, 15683
Not yet recruiting
Research Site
Somerset, New Jersey, 08873
Not yet recruiting
Research Site
St Louis, Missouri, 63141
Not yet recruiting
Research Site
Stow, Ohio, 44224
Not yet recruiting
Research Site
Torrance, California, 90503
Not yet recruiting
Research Site
Tucson, Arizona, 85715
Not yet recruiting
Research Site
Walnut Creek, California, 94598
Not yet recruiting
Research Site
Warren Township, New Jersey, 07059
Not yet recruiting
Research Site
Woodstock, Georgia, 30189
Recruiting

Other trials in United States

Germany20 sites, 20 recruiting

Research Site
Berlin, 10117
Not yet recruiting
Research Site
Berlin, 10629
Not yet recruiting
Research Site
Bochum, 44789
Not yet recruiting
Research Site
Bünde, 32257
Not yet recruiting
Research Site
Dresden, 01069
Not yet recruiting
Research Site
Frankfurt, 60590
Not yet recruiting
Research Site
Frankfurt, 60596
Not yet recruiting
Research Site
Freiburg im Breisgau, 79106
Not yet recruiting
Research Site
Göttingen, 37075
Not yet recruiting
Research Site
Hamburg, 20095
Not yet recruiting
Research Site
Hamburg, 20253
Not yet recruiting
Research Site
Hanover, 30159
Not yet recruiting
Research Site
Homburg, 66421
Not yet recruiting
Research Site
Jerichow, 39319
Not yet recruiting
Research Site
Karlsruhe, 76137
Not yet recruiting
Research Site
Leipzig, 04177
Not yet recruiting
Research Site
Magdeburg, 39110
Not yet recruiting
Research Site
Mainz, 55128
Not yet recruiting
Research Site
München, 80339
Not yet recruiting
Research Site
Offenbach, 63065
Not yet recruiting

Other trials in Germany

Canada18 sites, 17 recruiting

Research Site
Calgary, Alberta, T3R 1W9
Recruiting
Research Site
Hamilton, Ontario, L8L 5G8
Recruiting
Research Site
Joliette, Quebec, J6E 6A9
Recruiting
Research Site
Markham, Ontario, L3S 0A2
Recruiting
Research Site
Moncton, New Brunswick, E1G 1A7
Recruiting
Research Site
Montreal, Quebec, H4J 1E3
Recruiting
Research Site
Montreal, Quebec, H4N 2W2
Recruiting
Research Site
North York, Ontario, M6B 3H7
Recruiting
Research Site
Québec, Quebec, G2J 0C4
Recruiting
Research Site
Sarnia, Ontario, N7T 4X3
Recruiting
Research Site
Scarborough Village, Ontario, M1R 0B1
Recruiting
Research Site
Stoney Creek, Ontario, L8J 3W2
Withdrawn
Research Site
Stouffville, Ontario, L4A1H2
Recruiting
Research Site
Toronto, Ontario, M4G3E8
Recruiting
Research Site
Toronto, Ontario, M6G 1M2
Recruiting
Research Site
Trois-Rivières, Quebec, G9A 4P3
Recruiting
Research Site
Truro, Nova Scotia, B2N 1L2
Recruiting
Research Site
Vancouver, British Columbia, V5Y 3W2
Recruiting

Other trials in Canada

China16 sites, 16 recruiting

Research Site
Beijing, 100050
Not yet recruiting
Research Site
Cangzhou, 061001
Not yet recruiting
Research Site
Changchun, 130011
Not yet recruiting
Research Site
Chengdu, 610021
Not yet recruiting
Research Site
Chengdu, 610072
Not yet recruiting
Research Site
Danyang, 212399
Not yet recruiting
Research Site
Ganzhou, 341000
Not yet recruiting
Research Site
Guangzhou, 510280
Not yet recruiting
Research Site
Huizhou, 516002
Not yet recruiting
Research Site
Huzhou, 313003
Not yet recruiting
Research Site
Lanzhou, 730000
Not yet recruiting
Research Site
Nanjing, 210008
Not yet recruiting
Research Site
Nanjing, 210009
Not yet recruiting
Research Site
Panjin, 124009
Not yet recruiting
Research Site
Suzhou, 215006
Not yet recruiting
Research Site
Xianyang, 712000
Not yet recruiting

Other trials in China

Japan16 sites, 16 recruiting

Research Site
Aira, 899-5421
Recruiting
Research Site
Chūōku, 1040031
Not yet recruiting
Research Site
Fukuoka, 814-0153
Recruiting
Research Site
Hachioji-shi, 192-0071
Not yet recruiting
Research Site
Izunokuni-shi, 410-2295
Recruiting
Research Site
Kumamoto, 860-0833
Recruiting
Research Site
Nagoya, 451-8511
Recruiting
Research Site
Nagoya, 467-0806
Recruiting
Research Site
Nerima-ku, 177-0051
Not yet recruiting
Research Site
Osaka, 537-0014
Recruiting
Research Site
Osaka, 540-0006
Recruiting
Research Site
Saga, 840-8571
Recruiting
Research Site
Sapporo, 060-0001
Not yet recruiting
Research Site
Shinjuku-ku, 160-0008
Recruiting
Research Site
Suita-shi, 565-0853
Not yet recruiting
Research Site
Tanabe-shi, 646-8558
Recruiting

Other trials in Japan

Poland15 sites, 14 recruiting

Research Site
Bialystok, 15-481
Not yet recruiting
Research Site
Elblag, 82-300
Not yet recruiting
Research Site
Gdynia, 81-338
Not yet recruiting
Research Site
Katowice, 40-081
Not yet recruiting
Research Site
Katowice, 40-772
Not yet recruiting
Research Site
Krakow, 30-105
Not yet recruiting
Research Site
Krakow, 31-271
Withdrawn
Research Site
Legnica, 59-220
Not yet recruiting
Research Site
Lodz, 90-132
Not yet recruiting
Research Site
Lodz, 90-338
Not yet recruiting
Research Site
Poznan, 60-354
Not yet recruiting
Research Site
Radzionków, 41-922
Not yet recruiting
Research Site
Warsaw, 00-719
Not yet recruiting
Research Site
Warsaw, 03-291
Not yet recruiting
Research Site
Wroclaw, 53-673
Not yet recruiting

Other trials in Poland

Hungary11 sites

Research Site
Balatonfüred, 8230
Withdrawn
Research Site
Budapest, 1024
Withdrawn
Research Site
Budapest, 1036
Withdrawn
Research Site
Budapest, 1132
Withdrawn
Research Site
Budapest, 1138
Withdrawn
Research Site
Debrecen, 4031
Withdrawn
Research Site
Debrecen, 4032
Withdrawn
Research Site
Miskolc, 3530
Withdrawn
Research Site
Nyíregyháza-Sóstóhegy, 4481
Withdrawn
Research Site
Szeged, 6725
Withdrawn
Research Site
Szolnok, 5000
Withdrawn

Other trials in Hungary

Taiwan11 sites, 11 recruiting

Research Site
Changhua, 500
Not yet recruiting
Research Site
Kaohsiung City, 80756
Recruiting
Research Site
Taichung, 402
Not yet recruiting
Research Site
Taichung, 404
Not yet recruiting
Research Site
Taichung, 407219
Recruiting
Research Site
Taichung, 433004
Recruiting
Research Site
Tainan, 704
Not yet recruiting
Research Site
Tainan, 710
Not yet recruiting
Research Site
Taipei, 10002
Not yet recruiting
Research Site
Taipei, 11490
Not yet recruiting
Research Site
Zhubei, 302
Not yet recruiting

Other trials in Taiwan

Slovakia10 sites, 10 recruiting

Research Site
Bratislava, 831 03
Not yet recruiting
Research Site
Bratislava, 83101
Not yet recruiting
Research Site
Bratislava, 83106
Not yet recruiting
Research Site
Košice, 040 01
Not yet recruiting
Research Site
Košice, 04022
Not yet recruiting
Research Site
Lučenec, 984 01
Not yet recruiting
Research Site
Námestovo, 02901
Not yet recruiting
Research Site
Prievidza, 97101
Not yet recruiting
Research Site
Rožňava, 048 01
Not yet recruiting
Research Site
Trebišov, 075 01
Not yet recruiting

Other trials in Slovakia

South Korea10 sites, 10 recruiting

Research Site
Busan, 48108
Not yet recruiting
Research Site
Daegu, 42601
Not yet recruiting
Research Site
Daejeon, 35233
Not yet recruiting
Research Site
Incheon, 403-720
Not yet recruiting
Research Site
Seoul, 01830
Not yet recruiting
Research Site
Seoul, 06351
Not yet recruiting
Research Site
Seoul, 08308
Not yet recruiting
Research Site
Seoul, 143729
Not yet recruiting
Research Site
Seoul, 150-713
Not yet recruiting
Research Site
Suwon, 16247
Not yet recruiting

Other trials in South Korea

Spain10 sites, 10 recruiting

Research Site
A Coruña, 15006
Not yet recruiting
Research Site
Alzira (Valencia), 46600
Not yet recruiting
Research Site
Barcelona, 08035
Not yet recruiting
Research Site
Castilleja de La Cuesta, Sevilla, 41950
Not yet recruiting
Research Site
Ferrol (A Coruña), 15404
Not yet recruiting
Research Site
Lleida, 25198
Not yet recruiting
Research Site
Málaga, 29010
Not yet recruiting
Research Site
Oviedo, 33011
Not yet recruiting
Research Site
Segovia, 40002
Not yet recruiting
Research Site
Seville, 41010
Not yet recruiting

Other trials in Spain

Chile9 sites, 9 recruiting

Research Site
Concepción, 4070060
Not yet recruiting
Research Site
Concepción, 4070196
Not yet recruiting
Research Site
Concepción, 4070566
Not yet recruiting
Research Site
Iquique, 1111442
Not yet recruiting
Research Site
Las Condes, 6770128
Not yet recruiting
Research Site
Providencia, 7500504
Not yet recruiting
Research Site
Santiago, 7510187
Not yet recruiting
Research Site
Santiago, 7691236
Not yet recruiting
Research Site
Santiago, 8331143
Not yet recruiting

Other trials in Chile

India9 sites, 9 recruiting

Research Site
Bangalore, 560092
Not yet recruiting
Research Site
Indore, 452010
Not yet recruiting
Research Site
Kolkata, 700014
Not yet recruiting
Research Site
Nagpur, 440010
Not yet recruiting
Research Site
Noida, 201310
Not yet recruiting
Research Site
Pune, 411021
Not yet recruiting
Research Site
Pune, 411057
Not yet recruiting
Research Site
Siliguri, 734012
Not yet recruiting
Research Site
Visakhapatnam, 530002
Not yet recruiting

Other trials in India

Argentina7 sites, 7 recruiting

Research Site
Buenos Aires, C1120AAC
Recruiting
Research Site
CABA, C1425HFA
Recruiting
Research Site
Ciudad de Buenos Aires, C1094AAD
Recruiting
Research Site
Mendoza, 5500
Recruiting
Research Site
Ramos Mejía, B1704ETD
Not yet recruiting
Research Site
Rosario, S2000PBJ
Recruiting
Research Site
San Nicolás, B2900DMH
Not yet recruiting

Other trials in Argentina

Australia6 sites, 6 recruiting

Research Site
Botany, 2019
Recruiting
Research Site
Camberwell, 3124
Recruiting
Research Site
Charlestown, 2290
Recruiting
Research Site
Helensvale, 4212
Recruiting
Research Site
Maroubra, 2035
Recruiting
Research Site
Waitara, 2077
Recruiting

Other trials in Australia

United Kingdom6 sites, 6 recruiting

Research Site
Chippenham, SN15 2SB
Recruiting
Research Site
Corby, NN17 2UR
Recruiting
Research Site
Corby, NN18 9EZ
Recruiting
Research Site
Dunfermline, KY12 0SU
Recruiting
Research Site
Hull, HU3 2PA
Recruiting
Research Site
Northwood, HA6 2RN
Recruiting

Other trials in United Kingdom

About this study

Official title: A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

Read the detailed description

This is a Phase III, global, randomized, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM) and obesity or overweight. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Conditions: Obesity or Overweight, Diabetes Mellitus, Type 2
Being tested: Lenbelintide, Placebo
Keywords: Obesity, Overweight, AZD6234, Lenbelintide, Diabetes Mellitus, Type 2
Medical subject headings: Obesity, Overweight, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

LenbelintideDrug
Also called AZD6234
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
PlaceboDrug
Placebo matching IMP dose injected subcutaneously, once a week.

Study groups in NCT07784270
Study group	Role	What they receive
AZD6234 Dose 1	Experimental	AZD6234 Dose 1 Receives: Drug: Lenbelintide
AZD6234 Dose 2	Experimental	AZD6234 Dose 2 Receives: Drug: Lenbelintide
Placebo	Placebo comparator	Matching placebo Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percent change in body weight from baseline at 68 weeks of treatment.
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
Measured: 68 weeks

Secondary outcomes (8)

Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on absolute change in weight
Measured: 68 weeks
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%
Measured: 68 weeks
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%
Measured: 68 weeks
Change in haemoglobin A1C from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 on haemoglobin A1C change
Measured: 68 weeks
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on waist circumference change
Measured: 68 weeks
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change
Measured: 68 weeks
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change
Measured: 68 weeks
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants
Measured: 68 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

20 Aug 20269 Aug 2028

First posted25 Aug 2026
Study start20 Aug 2026
Primary completion9 Aug 2028 (estimated)
Study completion9 Aug 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Obesity or OverweightStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: International, multi-centre, randomised, double-blind, placebo-controlled, parallel-group
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 1,500 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07784270
Sponsor's protocol ID: D8750C00012
Other IDs: 159494, 2025-524616-11, 2025
Acronym: SELENE 2
Status last verified: Oct 2026
First submitted: 6 Aug 2026
Last updated: 28 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Study at a glance

From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
ClinicalTrials.gov ID: NCT07784270
Acronym / sponsor ID: SELENE 2 / D8750C00012
Conditions: Obesity or Overweight, Diabetes Mellitus, Type 2
Keywords: Obesity, Overweight, AZD6234, Lenbelintide, Diabetes Mellitus, Type 2
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 1,500 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 20 Aug 2026 (actual)
Primary completion: 9 Aug 2028 (estimated)
Study completion: 9 Aug 2028 (estimated)
First posted: 25 Aug 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 3
Model description: International, multi-centre, randomised, double-blind, placebo-controlled, parallel-group

Arm	Type	Receives
AZD6234 Dose 1	Experimental	Drug: LenbelintideAZD6234 Dose 1
AZD6234 Dose 2	Experimental	Drug: LenbelintideAZD6234 Dose 2
Placebo	Placebo comparator	Drug: PlaceboMatching placebo

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (6 listed)

Males \& females (inclusive of all gender identities) age ≥18 years
BMI ≥27 kg/m2
Diagnosed with T2DM ≥90 days prior to Screening
HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation

Key exclusion criteria (8 listed)

Obesity primarily caused by other endocrine disorders
Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
Significant hepatobiliary disease and/or any of the following results at Screening:
Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
Use of insulin therapy for T2DM within 3 months prior to screening

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
LenbelintideAlso: AZD6234IMP injected subcutaneously, once a week. Unit dose strength as per CSP.	Drug	AZD6234 Dose 1, AZD6234 Dose 2
PlaceboPlacebo matching IMP dose injected subcutaneously, once a week.	Drug	Placebo

Primary outcome

Percent change in body weight from baseline at 68 weeks of treatment.
Time frame: 68 weeks
To evaluate the effect of AZD6234 compared to placebo in percent body weight change

8 secondary outcomes

Absolute change in weight (kg) from baseline at 68 weeks of treatment
Time frame: 68 weeks
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
Time frame: 68 weeks
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
Time frame: 68 weeks
Change in haemoglobin A1C from baseline at 68 weeks of treatment
Time frame: 68 weeks
Change in waist circumference (cm) from baseline at 68 weeks of treatment
Time frame: 68 weeks
Percent change in triglycerides from baseline at 68 weeks of treatment
Time frame: 68 weeks
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
Time frame: 68 weeks
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Time frame: 68 weeks

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Related trials for Obesity or Overweight

Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Obesity or Overweight
RecruitingPhase 1
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Overweight and/or Obesity, Healthy Participants
RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Overweight or Obesity
Active, not recruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes Mellitus, Overweight

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

230 sites in 16 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Lenbelintide in people with Obesity or Overweight and Diabetes Mellitus, Type 2, run by AstraZeneca at 230 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 230 sites in United States, Germany, Canada, China, Japan and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent change in body weight from baseline at 68 weeks of treatment. (time frame: 68 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07784270.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.